Structural insights into the therapeutic efficacy and resistance of mogamulizumab
Heo, Y.-S.To be published.
Experimental Data Snapshot
Starting Model: experimental
View more details
wwPDB Validation 3D Report Full Report
Macromolecule Content 
Entity ID: 1 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| heavy chain | 231 | Homo sapiens | Mutation(s): 0  | ![]() | |
Entity Groups | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
Sequence AnnotationsExpand | |||||
Reference Sequence | |||||
Entity ID: 2 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| light chain | 219 | Homo sapiens | Mutation(s): 0  | ![]() | |
Entity Groups | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
Sequence AnnotationsExpand | |||||
Reference Sequence | |||||
Entity ID: 3 | |||||
|---|---|---|---|---|---|
| Molecule | Chains | Sequence Length | Organism | Details | Image |
| C-C chemokine receptor type 4 | E [auth J], F [auth K] | 11 | Homo sapiens | Mutation(s): 0  | ![]() |
UniProt & NIH Common Fund Data Resources | |||||
GTEx:  ENSG00000183813  | |||||
Entity Groups | |||||
| Sequence Clusters | 30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity | ||||
| UniProt Group | P51679 | ||||
Sequence AnnotationsExpand | |||||
Reference Sequence | |||||
| Length ( Å ) | Angle ( ˚ ) |
|---|---|
| a = 41.27 | α = 87.2 |
| b = 67.44 | β = 82.7 |
| c = 87.83 | γ = 79.25 |
| Software Name | Purpose |
|---|---|
| PHENIX | refinement |
| XDS | data scaling |
| XDS | data reduction |
| MOLREP | phasing |
| PDB_EXTRACT | data extraction |
| Funding Organization | Location | Grant Number |
|---|---|---|
| Not funded | -- |